We are live on ! Find out more
ELVN icon

Enliven Therapeutics
ELVN

34 hedge funds and large institutions have $302M invested in Enliven Therapeutics in 2020 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

243% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 7

100% more funds holding

Funds holding: 17 → 34 (+17)

73% more capital invested

Capital invested by funds: $174M → $302M (+$128M)

0% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 4

0.56% less ownership

Funds ownership: 16.38% → 15.82% (-0.56%)

Holders
34
Holders Change
+17
Holders Change %
+100%
% of All Funds
0.7%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
24
Increased
4
Reduced
4
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$16.4M
2
BlackRock
BlackRock
New York
+$9.59M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$4.46M
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$2.3M
5
Northern Trust
Northern Trust
Illinois
+$1.61M

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$17.5M
2
DCM
Driehaus Capital Management
Illinois
-$4.12M
3
Morgan Stanley
Morgan Stanley
New York
-$3.9M
4
RSCM
Rock Springs Capital Management
Maryland
-$2.27M
5
DM
Deerfield Management
New York
-$2.13M
Name Holding Trade Value Shares
Change 		Change in
Stake
Wells Fargo
26
Wells Fargo
California
$76K +$77.2K +690 New
Deutsche Bank
27
Deutsche Bank
Germany
$70K +$70.7K +632 New
UBS Group
28
UBS Group
Switzerland
$43K +$43.8K +391 New
SO
29
STRS Ohio
Ohio
$35K +$36.4K +325 New
TRCT
30
Tower Research Capital (TRC)
New York
$22K +$22.4K +200 New
Legal & General Group
31
Legal & General Group
United Kingdom
$22K +$22.8K +204 New
Citigroup
32
Citigroup
New York
$19K +$18.8K +168 New
AIP
33
Ameritas Investment Partners
Nebraska
$12K +$12.2K +109 New
Bank of Montreal
34
Bank of Montreal
Ontario, Canada
$9K +$11.1K +99 New
DCM
35
Driehaus Capital Management
Illinois
– -$4.12M -64,294 Closed
MIM
36
Monashee Investment Management
Massachusetts
– -$1.12M -17,500 Closed
Goldman Sachs
37
Goldman Sachs
New York
– -$769K -12,000 Closed
Norges Bank
38
Norges Bank
Norway
– -$641K -10,000 Closed
Citadel Advisors
39
Citadel Advisors
Florida
– -$509K -7,942 Closed
ECM
40
ExodusPoint Capital Management
New York
– -$318K -4,957 Closed
PCM
41
Prelude Capital Management
New York
– -$31K -476 Closed
1
2

ELVN Hedge Fund Activity: Q2 2020 in Review

34 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Enliven Therapeutics (ELVN) for Q2 2020, worth a combined $302M — up 73% from $174M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new ELVN positions and 7 closed out — a net gain of 17 holders — while 4 added to existing stakes and 4 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $16.4M. The largest seller was RA Capital Management, cutting an estimated $17.5M.

  • 34 institutional investors held Enliven Therapeutics (ELVN) as of Q2 2020, up from 17 in Q1 2020.
  • Funds reported $302M of Enliven Therapeutics stock for Q2 2020, up 73% quarter-over-quarter.
  • 24 funds opened new Enliven Therapeutics positions in Q2 2020 and 7 closed out, a net change of +17 holders.
  • The largest Enliven Therapeutics buyer in Q2 2020 was Fidelity Investments, an estimated $16.4M added.
  • The largest Enliven Therapeutics seller in Q2 2020 was RA Capital Management, an estimated $17.5M sold.

Based on aggregated 13F filings for Q2 2020.